

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4381721

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
FORMULATION TECHNOLOGIES LLC DBA PHARMAFORM	07/17/2008
RECEIVING PARTY DATA	
Name:	HIGHLAND THERAPEUTICS INC.
Street Address:	72 SAULTER STREET
Internal Address:	TORONTO
City:	ONTARIO
State/Country:	CANADA
Postal Code:	M4M 2H7
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15470705
CORRESPONDENCE DATA	
Fax Number:	(512)236-3377
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(512) 542-8459
Email:	iptldocket@velaw.com
Correspondent Name:	TIMOTHY S. CORDER, PATENT AGENT
Address Line 1:	VINSON & ELKINS LLP
Address Line 2:	1001 FANNIN STREET, SUITE 2500
Address Line 4:	HOUSTON, TEXAS 77002-6760
ATTORNEY DOCKET NUMBER:	IRO340/4-001CIP3CON5US
NAME OF SUBMITTER:	TIMOTHY S. CORDER, PATENT AGENT
SIGNATURE:	/Timothy S. Corder/
DATE SIGNED:	04/24/2017
Total Attachments: 6	
source=AssignmentPharmaformHighlandAgreement#page1.tif	
source=AssignmentPharmaformHighlandAgreement#page2.tif	
source=AssignmentPharmaformHighlandAgreement#page3.tif	
source=AssignmentPharmaformHighlandAgreement#page4.tif	

source=AssignmentPharmaformHighlandAgreement#page5.tif

source=AssignmentPharmaformHighlandAgreement#page6.tif



MASTER DEVELOPMENT AGREEMENT

BY AND BETWEEN

HIGHLAND THERAPEUTICS INC.

AND

FORMULATION TECHNOLOGIES L.L.C.

d/b/a PharmaForm

DATED AS OF

July 17, 2008

TABLE OF CONTENTS

ARTICLE 1	DEFINITIONS	4
ARTICLE 2	SERVICES	9
2.1	Development Program.....	9
2.2	Regulatory Filings and Meetings.....	9
2.3	Drug Substance and Safety Information.....	9
2.4	Timeline.....	9
2.5	Procurement of Materials.....	10
2.6	Reports.....	10
2.7	Patents.....	10
2.8	Intellectual Property Used in Performance of the Services.....	12
ARTICLE 3	PAYMENT OBLIGATIONS	12
3.1	Development Payment Schedule and Related Costs.....	12
3.2	Patent Payments.....	13
3.3	Clinical Supplies.....	13
ARTICLE 4	PHARMAFORM INTELLECTUAL PROPERTY DISCLOSURE	14
4.1	PharmaForm Disclosure.....	14
4.2	Acknowledgment.....	14
ARTICLE 5	INTELLECTUAL PROPERTY	14
5.1	Ownership and Assignment of Intellectual Property.....	14
5.2	Liability for Certain Decisions.....	15
5.3	Licenses.....	15
ARTICLE 6	CONFIDENTIALITY	16
6.1	Limitations on Disclosure and Use.....	16
6.2	Exception.....	16
6.3	Cooperation.....	17
6.4	Ownership.....	17
6.5	Trademarks and Trade Names.....	17
6.6	Remedies.....	17
6.7	Other Confidentiality Agreements.....	18
ARTICLE 7	NON-SOLICITATION	18
ARTICLE 8	PUBLICATION	18
8.1	Scientific Publications.....	18
8.2	Further Restrictions.....	19
ARTICLE 9	REGULATORY COMPLIANCE	19



ARTICLE 10 REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION 19

 10.1 Representations and Warranties 19

 10.2 Indemnification Covenants 20

 10.3 Duty to Indemnify 22

 10.4 Limitation of Liability 22

ARTICLE 11 TERM AND TERMINATION 23

 11.1 Term of Agreement 23

 11.2 Termination of Agreement 23

ARTICLE 12 MISCELLANEOUS 25

 12.1 Remedies For Breach of Restrictive Covenants 25

 12.2 Complete Agreement 25

 12.3 Notice 25

 12.4 Independent Contractor 26

 12.5 Assignment 26

 12.6 Force Majeure 27

 12.7 No Waiver 27

 12.8 Severability 27

 12.9 Governing Law and Venue 28

 12.10 Binding Agreement 28

 12.11 No Third Party Beneficiaries 28

 12.12 Survival 28

 12.13 Headings; Interpretation 28

 12.14 Amendment 28

 12.15 Counterparts 28



MASTER DEVELOPMENT AGREEMENT

This Master Development Agreement (this "Agreement") is made by and between Formulation Technologies L.L.C., a Texas limited liability company ("PharmaForm"), having a place of business at 11400 Burnet Road, Suite 4010, Austin, Texas 78758 and Highland Therapeutics Inc., a corporation having a place of business at 72 Saniter Street, Toronto, Ontario, Canada M4M 2H7 ("Client").

RECITALS

A. PharmaForm is in the business of pharmaceutical drug product research, development, characterization, manufacturing and commercialization, for itself, its Affiliates and Third Parties.

B. Client is in the business of developing pharmaceutical products for the treatment of ADHD.

C. Client desires to engage PharmaForm and PharmaForm desires to be engaged to provide the Services (defined below), all in accordance with the terms and conditions set forth in this Agreement and the attached R&D Plan.

AGREEMENT

For good and valuable consideration, including the mutual covenants herein contained, the parties hereto hereby agree as follows:

ARTICLE 1.

DEFINITIONS

"Affiliate" means, as to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common

ARTICLE 5.

INTELLECTUAL PROPERTY.

5.1 Ownership and Assignment of Intellectual Property. Client shall be the sole owner of all Results, and PharmaForm hereby irrevocably, immediately and exclusively assigns and, to the extent any such assignment cannot be made at present, agrees promptly to assign all its right, title and interest in and to any and all Results to Client. PharmaForm shall ensure that all its employees and agents performing any or all of the Services are obligated under a binding written agreement to assign in full to PharmaForm all Results. PharmaForm shall keep and maintain full and accurate records concerning all work performed in connection with the Services.



IN WITNESS WHEREOF, the parties have executed this Agreement to be effective as of the 17 day of July, 2008 (the "Effective Date").

PHARMAFORM:

Michael M. Crowley
By: Michael M. Crowley, Ph.D.
Its: Vice President, Business Development

CLIENT:

[Signature]
By: David Lickrish
Its: Chairman and Chief Executive Officer

11400 Harvest Road
Building 4, Suite 4010
Austin, Texas 78738

Confidential
Page 25 of 30

Tel (512) 234-0449
Fax (512) 234-2103
www.pharmaform.com

DOCSTOR: 14962473

PATENT